Immunocore Holdings (IMCR) Prepaid Assets (2020 - 2026)
Immunocore Holdings (IMCR) posted Prepaid Assets of $69.6 million for Q1 2026, up 34.16% sequentially from $51.9 million in Q4 2025, and up 66.89% YoY from $41.7 million in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Prepaid Assets (2020 - 2026) Analysis & Trends
Immunocore Holdings has reported Prepaid Assets for 7 years, with the latest figure at $69.6 million in Q1 2026.
- Quarterly Prepaid Assets rose 66.89% year-over-year to $69.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.6 million (up 66.89% YoY) and the FY2025 annual result came in at $51.9 million, up 26.41% from the prior year.
- Prepaid Assets rose to $69.6 million in Q1 2026 per IMCR's latest filing, from $51.9 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $69.6 million in Q1 2026 and troughed at $7.3 million in Q4 2022.
- A 5-year average of $39.6 million and a median of $41.0 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets jumped 302.87% in 2023, then advanced 26.41% in 2025.
- Over 5 years, Prepaid Assets stood at $7.3 million in 2022, then surged by 302.87% to $29.6 million in 2023, then surged by 38.62% to $41.0 million in 2024, then rose by 26.41% to $51.9 million in 2025, then jumped by 34.16% to $69.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $69.6 million, $51.9 million, and $49.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.69 Mn |
| Mar 31, 2026 | 69.59 Mn |
| Dec 31, 2025 | 51.87 Mn |
| Sep 30, 2025 | 48.96 Mn |
| Jun 30, 2025 | 44.27 Mn |
| Mar 31, 2025 | 41.70 Mn |
| Dec 31, 2024 | 41.03 Mn |
| Sep 30, 2024 | 36.45 Mn |
| Jun 30, 2024 | 33.56 Mn |
| Mar 31, 2024 | 31.30 Mn |
| Dec 31, 2023 | 29.60 Mn |
| Dec 31, 2022 | 7.35 Mn |
| Dec 31, 2021 | 5.37 Mn |
| Dec 31, 2020 | 4.53 Mn |